Showing results (91-100 of 102) with videos related to
Sort By:
Pageof 11
BJU International|July 24, 2020
Risk stratification for the prediction of overall survival could assist treatment decision-making at diagnosis of castration-resistant prostate cancer: a multicentre collaborative study in JapanTaizo Uchimoto, Kazumasa Komura, Wataru Fukuokaya, et al.Journal of Clinical Medicine|August 22, 2019
Comparison of Radiographic Progression-Free Survival and PSA Response on Sequential Treatment Using Abiraterone and Enzalutamide for Newly Diagnosed Castration-Resistant Prostate Cancer: A Propensity Score Matched Analysis from Multicenter CohortKazumasa Komura, Yuya Fujiwara, Taizo Uchimoto, et al.Gynecologic Oncology|February 28, 2022
Surgical skill and oncological outcome of laparoscopic radical hysterectomy: JGOG1081s-A1, an ancillary analysis of the Japanese Gynecologic Oncology Group Study JGOG1081Eiji Kobayashi, Eiji Nakatani, Tomohito Tanaka, et al.Medical Oncology (Northwood, London, England)|November 23, 2019
Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancerTaizo Uchimoto, Kazumasa Komura, Yuya Fujiwara, et al.Cancers|February 12, 2021
Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate CancerTaizo Uchimoto, Kazumasa Komura, Wataru Fukuokaya, et al.Cancers|July 24, 2021
Risk Classification for Overall Survival by the Neutrophil-Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab-A Multicenter Collaborative Study in JapanTaizo Uchimoto, Kazumasa Komura, Wataru Fukuokaya, et al.Cancer Science|September 27, 2023
Tertiary lymphoid structure and neutrophil-lymphocyte ratio coordinately predict outcome of pembrolizumabKazumasa Komura, Satoshi Tokushige, Mitsuaki Ishida, et al.Journal for Immunotherapy of Cancer|January 18, 2022
Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancerKazuki Nishimura, Kyosuke Nishio, Kensuke Hirosuna, et al.Molecular Cancer|November 19, 2023
The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder CancerKazumasa Komura, Kensuke Hirosuna, Satoshi Tokushige, et al.Cancer Treatment and Research Communications|March 7, 2026
Lenvatinib plus pembrolizumab for advanced or recurrent endometrial cancer: a retrospective multi-institutional survey in the Kinki district of JapanYasushi Mabuchi, Kyoka Takahashi, Takuya Yokoe, et al.Pageof 11